Dublin, Oct. 08, 2018 (GLOBE NEWSWIRE) -- The "Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth" report has been added to ResearchAndMarkets.com's offering.

The premium products market size for orphan and rare dermatology therapeutics is expected to grow, from $1.64 billion in 2017 to $6.07 billion in 2024, at a CAGR of 20.5%.

Dermatology is a highly diverse therapy area, in terms of severity and clinical presentation, which deals with diseases of the skin, hair and nails. Whilst an orphan disease is a disease that is neglected in terms of research and funding and in the US, a disease is considered to be rare if it affects fewer than 200,000 people.

Many orphan and rare dermatology disorders are associated with significant quality of life impairments, particularly if the disease is insufficiently controlled. In particular, disease visibility can have a profoundly negative impact on patient confidence. However, the current therapeutics market is a highly genericized therapy area and there exists a significant unmet need for more efficacious and safer treatment options that treat the underlying causes of disease as opposed to managing the symptoms.

This report covers all orphan and rare dermatology disorders, but there is a particular focus on six key diseases, systemic sclerosis (scleroderma), alopecia, epidermolysis bullosa, pemphigus vulgaris, vitiligo and cutaneous lupus erythematosus, as these conditions have the largest pipelines within the therapy area.

Scope

• The orphan and rare dermatology market landscape is expected to change and grow. Novel targets are expected to enter the market and drive market growth with a move towards disease modifying drugs instead of drugs which manage symptoms.
• Overall, there are 262 orphan and rare dermatology products in the pipeline.
• Which molecular targets are most prominent within the pipeline?
• How do the key indications differ in terms of molecule type?
• How does the composition of the pipeline compare with that of the existing market?
• What mechanisms of action are most common for pipeline drugs?
• Which products will contribute to market growth most, and will any achieve blockbuster status?
• Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the orphan and rare dermatology market set to change?
• What CAGR will these companies register in the forecast period?
• How many strategic consolidations have been completed in the past decade?
• Which types of assets attract the largest deal values?

Key Topics Covered:

1 Table of Contents

2 Introduction

2.1 Therapy Area Overview
2.1.1 Overview of the Dermatology Market
2.1.2 Overview of Orphan and Rare Diseases
2.1.3 Overview of Orphan and Rare Dermatological Diseases
2.2 Symptoms
2.3 Diagnosis
2.3.1 Systemic Sclerosis
2.3.2 Alopecia
2.3.3 Epidermolysis Bullosa
2.3.4 Pemphigus Vulgaris
2.3.5 Vitiligo
2.3.6 Cutaneous Lupus Erythematosus
2.4 Etiology
2.5 Pathophysiology
2.6 Epidemiology
2.7 Co-morbidities and Complications
2.8 Prognosis
2.9 Treatment

3 Key Marketed Products

3.1 Overview
3.2 Premium Drugs
3.2.1 Humira (adalimumab) - AbbVie
3.2.2 Ilaris (canakinumab) - Novartis
3.2.3 Afinitor (everolimus) - Novartis
3.2.4 Kineret (anakinra) - Swedish Orphan Biovitrum
3.2.5 Arcalyst (rilonacept) - Regeneron Pharmaceuticals
3.2.6 Tracleer (bosentan) - Johnson & Johnson
3.2.7 Thalomid (thalidomide) - Celgene
3.3 Highly Genericized Drugs
3.3.1 Medrol (methylprednisolone) - Pfizer
3.3.2 Meticorten/Rayos (Prednisone) - Merck & Co./Horizon Pharma

4 Pipeline Landscape Assessment

4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type and Program Type
4.2.1 Overall Pipeline
4.2.2 Pipeline by Key Indication
4.3 Molecular Targets in the Pipeline
4.3.1 Overall Pipeline
4.3.2 Pipeline by Key Indication
4.4 Clinical Trials Landscape
4.4.1 Challenges Associated with Clinical Trials for Orphan and Rare Diseases
4.4.2 Incentives for Clinical Trials for Orphan and Rare Diseases
4.4.3 Clinical Trial Failure Rates
4.4.4 Clinical Trial Duration
4.4.5 Clinical Trial Size
4.4.6 Cumulative Clinical Trial Size
4.5 Assessment of Key Pipeline Products
4.5.1 Epidiolex (cannabidiol) - GW Pharmaceuticals
4.5.2 Episalvan (birch bark extract) - Amryt Pharma
4.5.3 KB-103 - Krystal Biotech
4.5.4 Givosiran - Alnylam Pharmaceuticals
4.5.5 EB-101 - Abeona Therapeutics
4.5.6 OTL-103 - Orchard Therapeutics
4.5.7 Siponimod - Novartis
4.5.8 FCX-007 - Fibrocell Science

5 Multi-scenario Market Forecast to 2024

5.1 Market Size
5.2 Revenue Forecast by Molecular Target
5.2.1 Products Acting on Interleukins
5.2.2 Products Acting on Tumor Necrosis Factor-Alpha
5.2.3 Products Acting on Tyrosine Protein Kinases
5.2.4 Products Acting on Hormones and Hormone Receptors

6 Company Analysis and Positioning

6.1 Revenue and Market Share Analysis by Company
6.1.1 Novartis
6.1.2 GW Pharmaceuticals
6.1.3 AbbVie
6.1.4 Roche
6.1.5 Pfizer
6.1.6 Amryt Pharma
6.1.7 GlaxoSmithKline
6.1.8 Celgene
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Key Indication and Value
7.1.3 Deals by Stage of Development and Value
7.1.4 Deals by Molecule Type, Molecular Target and Value
7.1.5 Licensing Deals with Disclosed Values
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Key Indication and Value
7.2.3 Deals by Stage of Development and Value
7.2.4 Deals by Molecule Type, Molecular Target and Value
7.2.5 Co-development Deals with Disclosed Values

8 Appendix

Companies Mentioned

• AbbVie
• Novartis
• Swedish Orphan Biovitrum
• Regeneron Pharmaceuticals
• Johnson & Johnson
• Celgene
• Pfizer
• Merck & Co.
• Horizon Pharma

For more information about this report visit https://www.researchandmarkets.com/research/xvk5zv/global_orphan_and?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Dermatological Drugs